Former Senior Vice President, Chief Financial Officer and Treasurer · Akebia Therapeutics, Inc. (AKBA)

Jason Amello

A named executive officer of Akebia Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,025,928

Salary $267,640Stock awards $336,350

FY2019: $1,495,724

7th of 7 named executive officers at Akebia Therapeutics by FY2020 total.

7 named officers on file for Akebia Therapeutics, FY2020

Jason Amello’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • AKBA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Akebia Therapeutics’s whole pay program stands against its peers

  • Akebia Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AKBA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 22, 2021 (DEF 14A).

Free

Get Jason Amello’s full pay file as a PDF — free

More than this page: up to 10 years of Jason’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jason Amello compensation by year

Akebia Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Akebia Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020
Salary$380,438$417,953$267,640
Bonus$0$0$0
Stock awards$278,850$473,200$336,350
Option awards$272,553$444,477$253,917
Non-equity incentive$157,182$158,094$0
Pension and deferred compensation$0$0$0
All other$2,000$2,000$168,021
Total$1,091,023$1,495,724$1,025,928

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akebia Therapeutics, Inc. DEF 14A filed April 22, 2021, accession 0001193125-21-126686, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Akebia Therapeutics, Inc. filed document, accession 0001193125-21-126686. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2021.

$1.1M
$1.5M
$1.0M
FY18
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU93,334$261,335—
Option45,000—$8.87
Option37,500—$7.28

Per the Outstanding Equity Awards at Fiscal Year-End table in Akebia Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Akebia Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
John ButlerPresident and Chief Executive Officer$5,930,437
David SpellmanSenior Vice President, Chief Financial Officer and Treasurer$2,804,498
Michel DahanSenior Vice President, Chief Operating Officer$2,012,124
Steven BurkeSenior Vice President, Chief Medical Officer$1,919,351
Nicole HadasSenior Vice President, Chief Legal Officer$1,844,845
Dell FaulkinghamSenior Vice President, Chief Commercial Officer$1,759,476
Jason Amello · this pageFormer Senior Vice President, Chief Financial Officer and Treasurer$1,025,928

The full Akebia Therapeutics compensation record

free company brief

This page is one person within Akebia Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Akebia Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akebia Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jason Amello's compensation dossier · One-time report. No refunds.